Search

Your search keyword '"Ber Nieto Y"' showing total 2 results
Start Over Author "Ber Nieto Y" Topic iron
2 results on '"Ber Nieto Y"'

1. Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment.

Author

Bastida G, Herrera-de Guise C, Algaba A, Ber Nieto Y, Soares JM, Robles V, Bermejo F, Sáez-González E, Gomollón F, and Nos P

Subjects
Administration, Oral, Adult, Aged, Aged, 80 and over, Anemia, Iron-Deficiency complications, Dietary Supplements, Female, Ferric Compounds, Hemoglobins analysis, Humans, Inflammatory Bowel Diseases complications, Male, Middle Aged, Prospective Studies, Surveys and Questionnaires, Trace Elements administration & dosage, Treatment Outcome, Young Adult, Anemia, Iron-Deficiency drug therapy, Inflammatory Bowel Diseases drug therapy, Iron administration & dosage, Quality of Life
Abstract

Iron deficiency anemia (IDA) is a common manifestation of Inflammatory Bowel Disease (IBD). Oral iron supplements are the treatment of choice, but are not always well tolerated. Sucrosomial ® iron (SI) may represent an alternative. This prospective study assessed the tolerability and effectiveness of SI, and quality of life (QoL) of IDA-IBD patients who were intolerant to oral iron salts. The study included 52 individuals treated with 1 capsule/day for 12 weeks. Tolerability was assessed through a gastrointestinal symptom severity questionnaire. Hemoglobin (Hb) levels and clinical symptoms of IDA were analyzed. QoL was assessed using IBDQ-9 and EuroQoL questionnaires. The percentage of patients with excellent/good health increased from 42.9% to 94.3%. Mean Hb concentration significantly increased at all follow-up visits ( p < 0.05). Almost all participants (96.9%) were adherent to the study medication. Patients' QoL improved (IBDQ-9: from 60.9 to 65.5). Patients also improved in mobility (71.8% to 78.1%), usual activities (51.3% to 68.7%), pain/discomfort (41.0% to 53.1%), and extreme depression/anxiety problems (7.7% to 3.2%); they worsened in self-care (100% to 90.6%), but perceived an enhancement in their global health [EQ-VAS score: 61.9 (±26.1) to 66.9 (±20.3)]. SI was well tolerated and improved IDA symptoms, IBD activity, and patients' QoL. In conclusion, SI should be considered in IDA-IBD patients.

Published
2021
Full Text
View/download PDF

2. Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment

Author

V. Robles, Pilar Nos, Claudia Herrera-de Guise, Alicia Algaba, Yolanda Ber Nieto, Guillermo Bastida, Esteban Sáez-González, Fernando Gomollón, Jose Manuel Soares, Fernando Bermejo, Institut Català de la Salut, [Bastida G] Department of Gastroenterology, CIBEREHD, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain. [Herrera-de Guise C, Robles V] Unitat d'Atenció a la Colitis de Crohn, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Algaba A] Department of Gastroenterology, Instituto de Investigación Sanitaria Hospital La Paz (IdiPaz), Hospital Universitario de Fuenlabrada, 28046 Madrid, Spain. [Ber Nieto Y] Department of Gastroenterology, Hospital Universitario San Jorge, 22004 Huesca, Spain. [Soares JM] Department of Gastroenterology, Hospital Pedro Hispano, 4454-509 Matosinhos, Portugal, Vall d'Hebron Barcelona Hospital Campus, and Servicio de Digestivo. Hospital Universitario de Fuenlabrada

Subjects
enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo del hierro::anemia ferropénica [ENFERMEDADES], Male, Inorganic Chemicals::Elements::Metals, Heavy::Iron [CHEMICALS AND DRUGS], Administration, Oral, Gastroenterology, Inflammatory bowel disease, Ferric Compounds, Intestins - Inflamació - Tractament, enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal [ENFERMEDADES], Hemoglobins, Enfermedades Inflamatorias del Intestino, 0302 clinical medicine, iron deficiency, Quality of life, Surveys and Questionnaires, Compuestos de Hierro, Anèmia ferropènica - Tractament, TX341-641, Prospective Studies, Prospective cohort study, Depression (differential diagnoses), Aged, 80 and over, Nutrition and Dietetics, Anemia, Iron-Deficiency, sucrosomial iron, Iron deficiency, Middle Aged, anemia, humanities, compuestos inorgánicos::elementos::metales pesados::hierro [COMPUESTOS QUÍMICOS Y DROGAS], Anemia Ferropénica, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, Other subheadings::Other subheadings::/administration & dosage [Other subheadings], 030211 gastroenterology & hepatology, Female, Adult, medicine.medical_specialty, Anemia, Iron, Article, 03 medical and health sciences, Young Adult, inflammatory bowel disease, Internal medicine, medicine, Humans, Ferro - Metabolisme - Ús terapèutic, Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases [DISEASES], Aged, Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores], Nutrition. Foods and food supply, business.industry, iron supplementation, Nutritional and Metabolic Diseases::Metabolic Diseases::Iron Metabolism Disorders::Anemia, Iron-Deficiency [DISEASES], medicine.disease, Inflammatory Bowel Diseases, Trace Elements, Iron-deficiency anemia, Dietary Supplements, Quality of Life, business, Iron Compounds, Food Science
Abstract

Iron deficiency anemia (IDA) is a common manifestation of Inflammatory Bowel Disease (IBD). Oral iron supplements are the treatment of choice, but are not always well tolerated. Sucrosomial® iron (SI) may represent an alternative. This prospective study assessed the tolerability and effectiveness of SI, and quality of life (QoL) of IDA-IBD patients who were intolerant to oral iron salts. The study included 52 individuals treated with 1 capsule/day for 12 weeks. Tolerability was assessed through a gastrointestinal symptom severity questionnaire. Hemoglobin (Hb) levels and clinical symptoms of IDA were analyzed. QoL was assessed using IBDQ-9 and EuroQoL questionnaires. The percentage of patients with excellent/good health increased from 42.9% to 94.3%. Mean Hb concentration significantly increased at all follow-up visits (p &lt, 0.05). Almost all participants (96.9%) were adherent to the study medication. Patients’ QoL improved (IBDQ-9: from 60.9 to 65.5). Patients also improved in mobility (71.8% to 78.1%), usual activities (51.3% to 68.7%), pain/discomfort (41.0% to 53.1%), and extreme depression/anxiety problems (7.7% to 3.2%), they worsened in self-care (100% to 90.6%), but perceived an enhancement in their global health [EQ-VAS score: 61.9 (±26.1) to 66.9 (±20.3)]. SI was well tolerated and improved IDA symptoms, IBD activity, and patients’ QoL. In conclusion, SI should be considered in IDA–IBD patients.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results